



"Biomarkers" in medical imaging are the key to detecting and treating cancer

Press release

**MEDIAN Technologies to take part to the
8th Annual Imaging in Cancer Drug Development Conference,
London, UK.**

Sophia Antipolis, France, March 12th 2012 – MEDIAN Technologies (ALMDT), a leading services provider for images interpretation and management during oncology clinical trials and software provider for medical imaging, announces its participation as sponsor to the 8th Annual Imaging in Cancer Drug Development Conference, to be held next March 14-15th in London, UK.

During this conference, MEDIAN Technologies will make a presentation entitled *"Toward better imaging interpretation and management to leverage oncology clinical trial success rates"*. Today, images are used as surrogate endpoints in cancer drug development but their prominent role triggers new clinical and technological challenges ; the presentation will deal with the leading role of medical images in oncology clinical trials and will emphasize the significance of an optimized image interpretation and management workflow in this therapeutic area.

MEDIAN Clinical Trial Imaging Services (CTIS) offer as well as MEDIAN Lesion Management Solutions (LMS) portfolio will be presented on the MEDIAN booth during the conference.

The Imaging in Cancer Drug Development conference allows pharmaceutical companies, biotechnology companies and imaging CRO to review imaging practices and emergent technologies which enable to optimize oncology clinical trials.



MEDIAN

“Biomarkers” in medical imaging are the key to detecting and treating cancer

ALMDT
LISTED
NYSE
ALTERNEXT

About MEDIAN Technologies: Based in Sophia Antipolis, MEDIAN was founded in 2002 by Fredrik Brag (Current CEO), Gérard Milhiet and Arnaud Butzbach. The company has a staff of 40, over half of whom work in R&D, and has a subsidiary in the USA.

MEDIAN Technologies offers solutions and services for diagnosing and monitoring cancer patients for clinical trials market in oncology, its priority market, and the patient care market. MEDIAN collaborated with institutes at the cutting edge of medical imaging, among which the French National Institute for Computer Science and Control (INRIA), Chicago University and the Swiss Federal Institute of Technology in Lausanne, Switzerland (EPFL).

MEDIAN Technologies has been present in the market since 2007 through direct and indirect sales of its LMS solutions and alliances with specialist cancer centers in Europe and the USA.

For more information on MEDIAN, please visit: www.mediantechologies.com

Press Contacts

MEDIAN Technologies

Fredrik Brag, CEO

+33 4 92 90 65 82

fredrik.brag@mediantechnologies.com

ALIZE RP

Caroline Carmagnol

+ 33 6 64 18 99 59 // + 33 1 42 68 86 43

caroline@alizerp.com

Anne-Sophie Cosquéric

+ 33 1 42 68 86 41

Anne-sophie@alizerp.com